These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 9158517

  • 21. [Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels].
    Ortega A, Alonso JC, Suárez M, Domínguez P, Almoguera I, Bittini A, Gómez A, Martínez L, Herranz F, Pérez-Vázquez JM.
    Rev Esp Med Nucl; 2000 Oct; 19(6):409-15. PubMed ID: 11060270
    [Abstract] [Full Text] [Related]

  • 22. Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer.
    Singh OP, Yogi V, Redhu P, Ghori HU, Pareek A, Lal N.
    J Cancer Res Ther; 2019 Mar; 15(Supplement):S39-S41. PubMed ID: 30900618
    [Abstract] [Full Text] [Related]

  • 23. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
    Wolff JM, Bares R, Jung PK, Buell U, Jakse G.
    Urol Int; 1996 Mar; 56(3):169-73. PubMed ID: 8860738
    [Abstract] [Full Text] [Related]

  • 24. Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer.
    Rydh A, Tomic R, Tavelin B, Hietala SO, Damber JE.
    Scand J Urol Nephrol; 1999 Apr; 33(2):89-93. PubMed ID: 10360447
    [Abstract] [Full Text] [Related]

  • 25. The value of a baseline bone scan in patients with newly diagnosed prostate cancer.
    Lin K, Szabo Z, Chin BB, Civelek AC.
    Clin Nucl Med; 1999 Aug; 24(8):579-82. PubMed ID: 10439178
    [Abstract] [Full Text] [Related]

  • 26. Retrospective study of predictors of bone metastasis in prostate cancer cases.
    Ho CC, Seong PK, Zainuddin ZM, Abdul Manaf MR, Parameswaran M, Razack AH.
    Asian Pac J Cancer Prev; 2013 Aug; 14(5):3289-92. PubMed ID: 23803117
    [Abstract] [Full Text] [Related]

  • 27. [Bone scan findings in a North African ethnic group and relation to PSA level and Gleason score of the biopsy].
    Janane A, Jawad C, Hajji F, Ould T, Ghadouane M, Ameur A, Abbar M, Albouzidi A.
    Actas Urol Esp; 2011 Oct; 35(9):534-9. PubMed ID: 21664008
    [Abstract] [Full Text] [Related]

  • 28. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
    Spencer JA, Chng WJ, Hudson E, Boon AP, Whelan P.
    Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
    [Abstract] [Full Text] [Related]

  • 29. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.
    Lin Y, Mao Q, Chen B, Wang L, Liu B, Zheng X, Xie L.
    BMC Urol; 2017 Jun 12; 17(1):41. PubMed ID: 28606069
    [Abstract] [Full Text] [Related]

  • 30. Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
    Lee SH, Chung MS, Park KK, Yom CD, Lee DH, Chung BH.
    World J Urol; 2012 Apr 12; 30(2):265-9. PubMed ID: 21779835
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [The indication of bone scan for patients with newly diagnosed prostate cancer].
    Liu D, Wang W, Qiao LD, Zheng YP, Liu YX, Zhang GY, Chen S.
    Zhonghua Wai Ke Za Zhi; 2012 May 12; 50(5):443-5. PubMed ID: 22883953
    [Abstract] [Full Text] [Related]

  • 33. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis.
    Tanaka N, Fujimoto K, Shinkai T, Nakai Y, Kuwada M, Anai S, Miyake M, Hirayama A, Hasegawa M, Hirao Y.
    Jpn J Clin Oncol; 2011 Oct 12; 41(10):1209-13. PubMed ID: 21862505
    [Abstract] [Full Text] [Related]

  • 34. [When should we perform a bone scintigraphy in patients with new diagnosis of asymptomatic prostate cancer in order to detect bone metastasis?].
    Márquez-López J, Gómez-Gómez E, Anaya-Henares F, Robles-Casilda R, Requena-Tapia MJ.
    Arch Esp Urol; 2015 Mar 12; 68(2):135-41. PubMed ID: 25774820
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Correlation of prostatic specific antigen, tumor grade, and local stage with bone scintigraphy in the staging of patients with prostatic cancer].
    Herranz Amo F, Díez Cordero JM, Verdú Tartajo F, Lledó García E, Subirá Castillón C, González Chamorro F, Rodríguez Fernández E.
    Arch Esp Urol; 1997 Apr 12; 50(3):253-8. PubMed ID: 9144973
    [Abstract] [Full Text] [Related]

  • 37. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?
    Pal RP, Thiruudaian T, Khan MA.
    Asian J Androl; 2008 Nov 12; 10(6):890-5. PubMed ID: 18958353
    [Abstract] [Full Text] [Related]

  • 38. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
    KandaSwamy GV, Bennett A, Narahari K, Hughes O, Rees J, Kynaston H.
    BJU Int; 2017 Nov 12; 120(5B):E59-E63. PubMed ID: 28317247
    [Abstract] [Full Text] [Related]

  • 39. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.
    Al-Ghazo MA, Ghalayini IF, Al-Azab RS, Bani-Hani I, Barham A, Haddad Y.
    Int Braz J Urol; 2010 Nov 12; 36(6):685-91; discussion 691-2. PubMed ID: 21176275
    [Abstract] [Full Text] [Related]

  • 40. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?
    Gomez P, Manoharan M, Kim SS, Soloway MS.
    BJU Int; 2004 Aug 12; 94(3):299-302. PubMed ID: 15291855
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.